Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma

Rui Meng, Xueke Zhang, Ting Zhou, Mengjie Luo & Yijin Qiu
Donafenib and lenvatinib are approved by China National Medical Products Administration and recommended as first-line treatment of Metastatic Hepatocellular Carcinoma (HCC). The aim of this study was to assess the cost-effectiveness of donafenib compared with lenvatinib for first-line treatment of advanced HCC in China. A partitioned survival model consisting with three health states was developed to simulate lifetime development of advanced HCC from China healthcare payer’s perspective. The lifetime costs, quality-adjusted life-years (QALYs), life-years (LYs),...
1 citation reported since publication in 2022.
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.